A Study of the Interaction Between Tumor Susceptibility Gene Glycine N-methyltransferase (GNMT) and Lung Cancer

Sponsor
China Medical University Hospital (Other)
Overall Status
Unknown status
CT.gov ID
NCT01452971
Collaborator
(none)
200

Study Details

Study Description

Brief Summary

Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as the major risk factors for lung cancer development. In this proposal, the investigators collected fifteen kinds of major PAHs and the investigators would like to perform the following studies:

  1. Study the gene expression and subcellular localization of GNMT in the normal-tumor tissue pairs of lung cancer patients.

  2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the susceptibility to lung cancer;

  3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the normal-tumor tissue pairs of lung cancer patients.

  4. Study the associations of the copy number variation (CNV) of GNMT and the susceptibility to lung cancer;

  5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung cancer cell lines.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Multi-functional protein Glycine N-methyltransferase (GNMT, EC2.1.1.20, localized to chromosome 6p12), affects genetic stability by a) regulating the ratio of S-adenosylmethionine (SAM) to S-adenosylhomocystine (SAH) and b) binding to folate. Based on the following observations, GNMT is classified as a tumor susceptibility gene: a) diminished GNMT expression levels in both human hepatocellular carcinoma (HCC) cell lines and tissues;

    1. genotypic analyses of several human GNMT gene polymorphisms showed a loss of heterozygosity in 36-47% of the genetic markers in HCC tissues and also related to the susceptibility of prostate cancer; c) GNMT binds to environmental carcinogens such as benzo(a)pyrene (BaP) and aflatoxin B1 (AFB1) and protect the liver cells by inhibiting DNA-adduct formation.

    Environmental carcinogens such as polycyclic aromatic hydrocarbons (PAHs) were reviewed as the major risk factors for lung cancer development. In this proposal, the investigators collected fifteen kinds of major PAHs and would like to perform the following studies:

    1. Study the gene expression and subcellular localization of GNMT in the normal-tumor tissue pairs of lung cancer patients.

    2. Study the associations of the polymorphisms of GNMT in lung cancer patients and the susceptibility to lung cancer;

    3. To assess the allelic loss at GNMT and determined the LOH rate of GNMT in the normal-tumor tissue pairs of lung cancer patients.

    4. Study the associations of the copy number variation (CNV) of GNMT and the susceptibility to lung cancer;

    5. Study the interaction between GNMT and polycyclic aromatic hydrocarbons (PAHs) in lung cancer cell lines.

    So far, the investigators have analyzed the gene expression of GNMT in the normal-tumor tissue pairs of some lung cancer patients. The investigators also analyzed the interaction between the GNMT and some PAHs using lung cancer cell lines. These data are helpful to clarify the susceptibility of lung cancer patients with the gene expression in GNMT.

    This study is helpful in elucidating the role of GNMT plays in the tumorigenesis of lung cancer which may have important implications in the development of strategies for the prevention, diagnosis and treatment of lung cancer and other types of cancer.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    200 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Prospective
    Official Title:
    A Study of the Interaction Between Tumor Susceptibility Gene GNMT and Lung Cancer
    Study Start Date :
    Oct 1, 2011

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      No
      Inclusion Criteria:
      • Participant is a lung cancer patient.
      Exclusion Criteria:
      • Participant is under 18 years old.

      • Participant is not a lung cancer patient.

      Contacts and Locations

      Locations

      No locations specified.

      Sponsors and Collaborators

      • China Medical University Hospital

      Investigators

      None specified.

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      None provided.
      Responsible Party:
      China Medical University Hospital
      ClinicalTrials.gov Identifier:
      NCT01452971
      Other Study ID Numbers:
      • DMR99-IRB-196
      First Posted:
      Oct 17, 2011
      Last Update Posted:
      Oct 17, 2011
      Last Verified:
      Oct 1, 2011

      Study Results

      No Results Posted as of Oct 17, 2011